MK 0994Alternative Names: MK-0994
Latest Information Update: 30 Jan 2008
At a glance
- Originator Merck & Co
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 15 Feb 2006 Phase-I clinical trials in Glaucoma (unspecified route)